Discover the latest in pharmaceutical advancements with our September 2025 roundup. We're covering newly approved treatments like Rhapsido for chronic spontaneous urticaria, Palsonify for acromegaly, and Inluriyo for ESR1-mutated breast cancer. Learn about groundbreaking therapies, their impacts on patient care, and what these mean for healthcare professionals and patients alike.

• Rhapsido (remibrutinib) for the management of difficult chronic spontaneous urticaria in adults still experiencing symptoms despite antihistamine therapy.
• Palsonify (paltusotine) introduces a groundbreaking once-daily oral option for acromegaly, offering rapid control of growth hormone levels.
• Inluriyo (imlunestrant), a significant development for treating ESR1-mutated breast cancer in patients who have experienced disease progression after endocrine therapy.
• Forzinity (elamipretide hydrochloride) provides hope for children with Barth syndrome by improving muscle strength through mitochondrial support.
• Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), a quicker subcutaneous option for pembrolizumab administration, simplifying immunotherapy for melanoma and non-small cell lung cancer patients.

Chapters

• (00:25) - Intro
• (00:51) - Rhapsido
• (01:47) - Palsonify
• (02:48) - Inluriyo
• (03:33) - Forzinity
• (04:09) - Keytruda Qlex
• (04:45) - Outro

• X, Facebook, Youtube
• Signup to our newsletters
• Download the app